Immunotherapy of cancer through targeting of the p53 tumor antigen.
The expression of the p53 tumor suppressor protein is frequently increased in a great variety of human cancers, making this antigen an attractive candidate for targeting therapeutic T cell immunity. However, potential complications as a result of immunological tolerance or autoimmune pathology must be taken into account when exploiting this ubiquitously expressed auto-antigen for the immunotherapy of cancer.